<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002288</url>
  </required_header>
  <id_info>
    <org_study_id>014K</org_study_id>
    <secondary_id>23</secondary_id>
    <nct_id>NCT00002288</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System</brief_title>
  <official_title>Safety and Efficacy of Retrovir in HIV Infected Patients Having Neuropsychological Impairments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To assess the efficacy of Retrovir (AZT) therapy in the treatment of HIV Ab positive persons&#xD;
      with impairments in neuropsychological functioning. To assess the safety, virologic, and&#xD;
      immunologic effects of AZT therapy in HIV Ab positive persons with neuropsychological&#xD;
      impairment but minimal other symptomatology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Neuropsychological (NP) impairments more severe than described in the Inclusion&#xD;
             Criteria.&#xD;
&#xD;
          -  Evidence of nervous system dysfunction being caused by factors other than HIV&#xD;
             infection, including history of head trauma, multiple sclerosis, epilepsy, or presence&#xD;
             of concurrent central nervous system (CNS) infections or neoplasms, e.g.,&#xD;
             toxoplasmosis, primary or metastatic CNS lymphoma, progressive multifocal&#xD;
             leukoencephalopathy, cryptococcal or other fungal meningitis, and CNS tuberculous&#xD;
             infections.&#xD;
&#xD;
          -  Lymphoma or other tumor requiring cytotoxic chemotherapy.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other antiretroviral agents.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  AIDS or advanced ARC.&#xD;
&#xD;
          -  Neuropsychological (NP) impairments more severe than described above; i.e., defective&#xD;
             performance on NP test battery in 3 or more NP areas on the NP screening battery at 2&#xD;
             standard deviations below the mean.&#xD;
&#xD;
          -  Evidence of nervous system dysfunction being caused by factors other than HIV&#xD;
             infection, including history of head trauma, multiple sclerosis, epilepsy, or presence&#xD;
             of concurrent central nervous system (CNS) metastatic CNS lymphoma, progressive&#xD;
             multifocal leukoencephalopathy, cryptococcal or other fungal meningitis, and CNS&#xD;
             tuberculous infections.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral agents including zidovudine (AZT).&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 3 months of study entry:&#xD;
&#xD;
          -  Blood transfusion.&#xD;
&#xD;
        Impaired performance on a defined neuropsychological test battery.&#xD;
&#xD;
          -  Asymptomatic HIV infection.&#xD;
&#xD;
          -  Persistent generalized lymphadenopathy (PGL).&#xD;
&#xD;
          -  Early AIDS related complex (ARC).&#xD;
&#xD;
          -  Seropositive for human immunodeficiency virus (HIV) demonstrated by positive ELISA&#xD;
             test and confirmed by Western blot with no or minimal symptomatology or HIV infection.&#xD;
&#xD;
          -  Ability to give informed consent or a person with durable power of attorney who can&#xD;
             give informed consent.&#xD;
&#xD;
          -  Willingness to be followed by the originating medical center for 1 year.&#xD;
&#xD;
        History of drug or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Glaxo Wellcome Inc</name>
      <address>
        <city>Research Triangle Park</city>
        <state>North Carolina</state>
        <zip>27709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Neuropsychological Tests</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

